← Back to Home

One-year results announced for uveitic macular edema drug: FDA accepts vamikibart application

An intravitreal antibody targeting IL-6 offers the possibility of reducing the burden of steroid treatment. One-year follow-up shows that improvements in vision and edema can be maintained, but the efficacy evidence from the two Phase III trials is not entirely consistent.

By SURL BioNews

Even when inflammation inside the eye is controlled, fluid accumulating in the macula may still make it difficult for vision to recover. For patients with uveitic macular edema, treatment must both reduce edema and account for the costs of long-term medication use. On October 10, Roche announced one-year follow-up results for the investigational drug vamikibart and said that the U.S. Food and Drug Administration (FDA) had accepted its Biologics License Application, with a decision on approval expected by July 2027.

Vamikibart is a monoclonal antibody designed specifically for intravitreal injection that targets interleukin-6 (IL-6), which is involved in inflammation. Macular edema is currently often treated with steroids or off-label medications, while ocular steroids carry risks of increased intraocular pressure, glaucoma, and cataracts. This development effort therefore seeks to offer another way to control local inflammation, but these results do not yet establish whether it can replace existing treatments.

The Phase III MEERKAT and SANDCAT trials enrolled 245 and 256 adults, respectively, who were randomized to receive 0.25 mg or 1 mg of vamikibart or a sham injection procedure. Treatment was scheduled monthly in the initial phase, followed after week 16 by a follow-up phase with additional treatment as needed, continuing through week 52. The primary efficacy endpoint was set at week 16 and assessed the proportion of patients whose best-corrected visual acuity improved by at least 15 eye-chart letters from baseline; the focus of this announcement was whether improvements could persist through one year.

According to the ophthalmology publication Retinal Physician, at week 52, the proportions reaching this threshold for visual improvement in the low-dose, high-dose, and control groups in MEERKAT were 28.3%, 21.7%, and 6.3%, respectively; in SANDCAT, they were 23.4%, 17.3%, and 12.0%. In the latter trial, neither dose showed a nominally statistically significant difference from the control. Roche said that improvements in mean visual acuity and macular thickness were largely maintained in both trials, but this does not mean that every efficacy measure has been consistently confirmed.

Differences between the trials also appeared in the earlier primary analysis: both doses in MEERKAT achieved statistical significance at week 16, while the 1 mg group in SANDCAT did not. Because of the order of statistical testing, its 0.25 mg group could only be considered nominally significant and could not be regarded as having fully passed the prespecified testing procedure. This makes the one-year data more meaningful as supplementary evidence of sustained efficacy than as a resolution of the earlier inconsistency in the primary endpoint.

The number of treatments is another practical issue. Roche and its subsidiary Genentech said that, among patients eligible for subsequent as-needed treatment, approximately two-thirds required no further treatment after week 16, while most of those who needed additional treatment received only one extra injection. This proportion applies to a specific denominator and cannot be interpreted as meaning that all participants could maintain the same treatment schedule. Retinal Physician also reported that more than half of the control group required rescue treatment, compared with approximately 20% of the vamikibart groups. No new safety signals emerged during the as-needed treatment period, and no retinal occlusive vasculitis was observed, but one year of follow-up remains insufficient to rule out rare or longer-term risks.

According to the company announcement, the European Union, China, and Japan have also accepted the relevant applications. Acceptance means that a drug has entered the review process; it does not mean approval. Assessment of this nonsteroidal therapy must still weigh improvements in vision, resolution of edema, the need for rescue treatment, and safety together. Currently available public information comes primarily from conference presentations, company announcements, and conference reporting; a full analysis will help clarify why the two trials showed different strengths of efficacy.

References

  1. Roche
  2. Genentech
  3. Retinal Physician